Missedย NVDA?
Donโt Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities โ for free.
Home โบ Stocks โบ Aflac Inc. (AFL) Stock Forecast & Price Prediction United States | NYSE | Financial Services | Insurance - Life
$117.80
+1.35 (1.16%)Did AFL Make This Month's Elite Buy List?
We don't follow just any analyst โ only the top 3% with a proven track record make our cut. See if Aflac is one of their latest high-conviction picks.
Based on our analysis of 5 Wall Street analysts, AFL has a neutral consensus with a median price target of $112.00 (ranging from $99.00 to $130.00). The overall analyst rating is Hold (5.9/10). Currently trading at $117.80, the median forecast implies a -4.9% downside. This outlook is supported by 3 Buy, 8 Hold, and 3 Sell ratings.
The most optimistic forecast comes from Paul Newsome at Piper Sandler, projecting a 10.4% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
These are the latest 20 analyst ratings and price targets for AFL.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 26, 2026 | Piper Sandler | Paul Newsome | Overweight | Maintains | $130.00 |
| May 21, 2026 | Morgan Stanley | Nigel Dally | Equal-Weight | Maintains | $125.00 |
| May 5, 2026 | Wells Fargo | Equal-Weight | Maintains | $N/A | |
| May 1, 2026 | Piper Sandler | Overweight | Maintains | $N/A | |
| Apr 30, 2026 | Barclays | Underweight | Maintains | $N/A | |
| Apr 13, 2026 | Mizuho | Underperform | Maintains | $N/A | |
| Apr 10, 2026 | Keefe, Bruyette & Woods | Market Perform | Maintains | $N/A | |
| Apr 10, 2026 | Wells Fargo | Equal-Weight | Maintains | $N/A | |
| Apr 9, 2026 | UBS | Neutral | Maintains | $N/A | |
| Mar 26, 2026 | Keefe, Bruyette & Woods | Ryan Krueger | Market Perform | Reinstates | $113.00 |
| Feb 25, 2026 | Wells Fargo | Equal-Weight | Maintains | $N/A | |
| Jan 8, 2026 | Barclays | Underweight | Maintains | $N/A | |
| Jan 5, 2026 | JP Morgan | Neutral | Maintains | $N/A | |
| Dec 30, 2025 | Raymond James | Outperform | Maintains | $N/A | |
| Dec 22, 2025 | TD Cowen | Hold | Maintains | $N/A | |
| Dec 16, 2025 | Mizuho | Underperform | Initiates | $N/A | |
| Nov 17, 2025 | Morgan Stanley | Equal-Weight | Maintains | $N/A | |
| Nov 7, 2025 | Wells Fargo | Equal-Weight | Maintains | $N/A | |
| Nov 7, 2025 | Evercore ISI Group | Underperform | Maintains | $N/A | |
| Nov 5, 2025 | JP Morgan | Neutral | Maintains | $N/A |
The following stocks are similar to Aflac based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Aflac Inc. has a market capitalization of $59.96B with a P/E ratio of 13.5x. The company generates $18.11B in trailing twelve-month revenue with a 25.6% profit margin.
Revenue growth is +27.9% quarter-over-quarter, while maintaining an operating margin of +29.6% and return on equity of +16.5%.
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings โ tracked and updated every Monday and Thursday.
Offers supplemental health and life insurance.
The company operates through two segments, Aflac Japan and Aflac U.S., providing supplemental insurance products that cover out-of-pocket medical costs not addressed by primary plans. Revenue is generated mainly through the sale of these policies, marketed via independent agents, brokers, and worksite distribution, as well as digital channels.
Aflac is headquartered in Columbus, Georgia, and serves both individuals and businesses, focusing on financial protection against unexpected health-related expenses. The company's well-recognized supplemental products include cancer insurance, accident coverage, and critical illness plans, making it a significant player in the insurance market in the U.S. and Japan.
Financial Services
Insurance - Life
12,716
Mr. Daniel Paul Amos
United States
1984
GL is benefiting from premium growth, rising investment income and strong sales momentum across its insurance businesses.
Insurance stocks, including Aflac (NYSE: AFL), face volatility due to factors like natural disasters, interest rates, and claims inflation affecting earnings.
Aflac's stock may be influenced by environmental risks and economic factors, indicating potential volatility which can impact investor returns and portfolio strategies.
Aflac Incorporated (AFL) presented at the Morgan Stanley US Financials Conference, discussing its financial strategies and outlook for 2026.
Aflacโs presentation at a major financial conference signals its strategies and outlook, potentially influencing investor sentiment and stock performance.
Aflac Incorporated announced the appointment of Virgil R. as President of Aflac Incorporated and Aflac U.S. on June 1, 2026.
Leadership changes can impact company strategy and performance. Investors may reassess Aflac's future direction and stock volatility in response to changes in management.
Aflac (AFL) reported earnings 30 days ago; investors may want to monitor upcoming developments for potential stock movements.
Upcoming developments post-earnings can impact Aflac's stock performance, affecting investor sentiment and market positioning.
Eight companies are on track to become Dividend Kings, achieving 50+ years of consecutive dividend increases, with expected status by 2032, highlighting strong dividend growth for income-focused investors.
The mention of companies nearing Dividend King status signals potential stability and reliable income, appealing to income-focused investors seeking long-term growth and dividend security.
AFL has raised 65.9 billion Yen in Japan's bond market, capitalizing on strong investor demand for higher yields as foreign issuers increasingly seek Yen debt.
AFL's bond issuance indicates strong foreign interest in Yen debt, signaling robust demand for higher yields and potentially impacting currency stability and interest rate trends.
Based on our analysis of 5 Wall Street analysts, Aflac Inc. (AFL) has a median price target of $112.00. The highest price target is $130.00 and the lowest is $99.00.
According to current analyst ratings, AFL has 3 Buy ratings, 8 Hold ratings, and 3 Sell ratings. The stock is currently trading at $117.80. Always conduct your own research and consider your investment goals before making investment decisions.
Wall Street analysts predict AFL stock could reach $112.00 in the next 12 months. This represents a -4.9% decrease from the current price of $117.80. Please note that this is a projection by Wall Street analysts and not a guarantee.
The company operates through two segments, Aflac Japan and Aflac U.S., providing supplemental insurance products that cover out-of-pocket medical costs not addressed by primary plans. Revenue is generated mainly through the sale of these policies, marketed via independent agents, brokers, and worksite distribution, as well as digital channels.
The highest price target for AFL is $130.00 from Paul Newsome at Piper Sandler, which represents a 10.4% increase from the current price of $117.80.
The lowest price target for AFL is $99.00 from at , which represents a -16.0% decrease from the current price of $117.80.
The overall analyst consensus for AFL is neutral. Out of 5 Wall Street analysts, 3 rate it as Buy, 8 as Hold, and 3 as Sell, with a median price target of $112.00.
Stock price projections, including those for Aflac Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.